WallStSmart

Novartis AG ADR (NVS)vsWellgistics Health, Inc. Common Stock (WGRX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 242330% more annual revenue ($56.58B vs $23.34M). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).

NVS

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 4.0Quality: 5.5
Piotroski: 4/9Altman Z: 1.96

WGRX

Avoid

30

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-52.5%)

Margin of Safety

-52.5%

Fair Value

$109.60

Current Price

$147.85

$38.25 premium

UndervaluedFair: $109.60Overvalued
WGRXUndervalued (+60.3%)

Margin of Safety

+60.3%

Fair Value

$0.79

Current Price

$0.11

$0.68 discount

UndervaluedFair: $0.79Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$282.11B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

WGRX0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

NVS4 concerns · Avg: 3.0/10
PEG RatioValuation
2.484/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth
-9.3%2/10

Earnings declined 9.3%

WGRX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$14.57M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-928.0%2/10

ROE of -928.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bull Case : WGRX

WGRX has a balanced fundamental profile.

Bear Case : NVS

The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.

Bear Case : WGRX

The primary concerns for WGRX are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

NVS profiles as a declining stock while WGRX is a value play — different risk/reward profiles.

NVS is growing revenue faster at -0.7% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NVS scores higher overall (51/100 vs 30/100), backed by strong 23.9% margins. WGRX offers better value entry with a 60.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Wellgistics Health, Inc. Common Stock

HEALTHCARE · PHARMACEUTICAL RETAILERS · USA

Wellgistics Health, Inc. is a wholesaler and distributor of pharmaceutical products to pharmaceutical manufacturers and independent retail pharmacies in the United States. The company is headquartered in Tampa, Florida.

Want to dig deeper into these stocks?